Value of [68Ga]Ga-PSMA-11 PET/MRI in the Assessment of Liver Cirrhosis
A total of fifty-five (55) patients with liver cirrhosis will be enrolled in this study to produce and validate dedicated Ga-PSMA-PET/MRI acquisition protocols.

The specific hypotheses include:

Ga-PSMA PET/MRI may allow robust and reproducible noninvasive in vivo quantitation of hepatic macro and microhemodynamics in cirrhotic patients
Dedicated simultaneously acquired DWI sequences might quantitate liver fibrosis and improve hemodynamic quantitation.
Ga-PSMA PET/MRI may allow noninvasive and reproducible quantitation of portal venous hypertension and predict its evolution, as well as response to treatments
Ga-PSMA PET/MRI may improve noninvasive and reproducible qualitative and quantitative assessment of liver function, structure, nodules and predict evolution of cirrhosis
- EligibilityCriteria: Inclusion Criteria:  Liver cirrhosis as diagnosed by imaging and/or clinical data, including pathology  Exclusion Criteria:  Any contraindication to PET, as in attached screening form Any contraindication to MRI, as in attached screening form Any contraindication to gadolinium-based contrast agent, including allergy to gadolinium, as in attached screening forms. Pregnancy Breast feeding. Cumulative radiation exposure for research studies during the prior 12 months, combined with the exposure from this study, > 50 mSv Inability to fit in the scanner: weight > 300 lbs or BMI > 33 - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - MaximumAge: 99 Years - StdAgeList: Adult, Older Adult - StudyPopulation: Fifty-five subjects will be recruited. All subjects recruited for the study will be able to withdraw from the study at any time.  Healthy Volunteers: The investigators will not be recruiting or enrolling healthy volunteers in this study. Patients with liver cirrhosis: Fifty-five (55) - SamplingMethod: Non-Probability Sample